PDCD1 and neoplasm: For example, by regulating the expression of immune inhibitory molecules such as PD-L1, m6A modification can enhance tumor immune escape and weaken the therapeutic efficacy of immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 antibodies).